Topics Covered:
• Overview of the CONTACT-02 trial
• Patient selection for mCRPC treatments
• The role of genetic testing in treatment decisions
• Managing side effects of combination therapies
• Future implications for FDA approval
Dr. Chinmay Jani from University of Miami in conversation with Dr. Tian Zhang from UT Southwestern Simmons Comprehensive Cancer Center
Dr. Chinmay Jani in conversation with Dr. Tian Zhang, discussed pressing challenges in treating metastatic castration-resistant prostate cancer (mCRPC).
Dr. Zhang discussed the CONTACT-02 trial, focusing on patient selection criteria, the significance of visceral metastases, and the potential impact of cabozantinib combined with atezolizumab on treatment strategies. Dr. Zhang highlighted the importance of genetic testing, the sequencing of treatments, and the management of side effects associated with these therapies.